Korea CDC Promoted To Independent Infectious Disease 'Control Tower' Amid COVID-19
Policy And Research Role Redefined
In the midst of the ongoing COVID-19 pandemic, Korea promotes its Centers For Disease Control & Prevention to a central administrative agency that will act as an infectious disease "control tower" that independently carries out investigation and research and sets infectious disease policy. A dedicated vice-minister of health and welfare has also been appointed to step up the public health and medical system.
You may also be interested in...
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.